Participation in Upcoming Investor Conferences

MaxCyte, Inc.

07 November 2023

 

MaxCyte to Participate in Two Upcoming Investor Conferences

Rockville, MD, November 7, 2023 - MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and innovative bioprocessing applications, today announced Company management will participate at two upcoming investor conferences.

·    Stifel 2023 Healthcare Conference

Fireside Chat on Wednesday, November 15^th at 9:10 ET  

·    Stephens Annual Investment Conference

Fireside Chat on Thursday, November 16^th at 9:00 CT

A live and archived webcast of the event will be available on the "Events" section of the MaxCyte investor relations website at https://investors.maxcyte.com/.

About MaxCyte

At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients' lives. We have spent more than 20 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today's processes to innovate tomorrow's solutions. Our ExPERT™ platform, which is based on our Flow Electroporation technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™, GTx™ and VLx™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology platform, as well as scientific, technical and regulatory support, we aim to guide them on their journey to transform human health. Learn more at maxcyte.com and follow us on Twitter and LinkedIn.

MaxCyte Contacts:

US IR Adviser 

Gilmartin Group 

David Deuchler, CFA 

[phone] 

[e-mail]  

US Media Relations 

Spectrum Seismic Collaborative 

Valerie Enes 

[phone] 

[e-mail] 

Nominated Adviser and Joint Corporate Broker 

Panmure Gordon 

Emma Earl / Freddy Crossley 

Corporate Broking 

Rupert Dearden 

[phone] 

UK IR Adviser 

ICR Consilium Strategic Communications 

Mary-Jane Elliott 

Chris Welsh 

[phone] 

[e-mail] 

 

END